Emergent BioSolutions Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
EBS$6.05-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders' Equity—
| $0.001 Par Value Common Stock · Treasury Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||
| Balance at December 31, 2025 | 60.9 | $0.1 | (8.7) | $(252.6) | $942.4 | $(7.5) | $(159.8) | $522.6 |
| Net income | — | $— | — | $— | $— | $— | $6.8 | $6.8 |
| Stock-based compensation activity | 0.5 | — | — | — | 2.1 | — | — | 2.1 |
| Repurchases of common stock | — | — | (0.9) | (9.0) | — | — | — | (9.0) |
| Other comprehensive income, net of tax | — | — | — | — | — | 0.6 | — | 0.6 |
| Balance at March 31, 2026 | 61.4 | $0.1 | (9.6) | $(261.6) | $944.5 | $(6.9) | $(153.0) | $523.1 |
| Net loss | — | $— | — | $— | $— | $— | $(180.2) | $(180.2) |
| Stock-based compensation activity | 0.5 | — | — | — | 7.3 | — | — | 7.3 |
| Repurchases of common stock | — | — | (1.1) | (8.9) | — | — | — | (8.9) |
| Other comprehensive income, net of tax | — | — | — | — | — | 0.1 | — | 0.1 |
| Balance at June 30, 2026 | 61.9 | $0.1 | (10.7) | $(270.5) | $951.8 | $(6.8) | $(333.2) | $341.4 |
| Net loss | — | $— | — | $— | $— | $— | $(32.7) | $(32.7) |
| Stock-based compensation activity | 0.1 | — | — | — | 4.8 | — | — | 4.8 |
| Repurchases of common stock | — | — | — | (0.2) | — | — | — | (0.2) |
| Other comprehensive loss, net of tax | — | — | — | — | — | (0.1) | — | (0.1) |
| Balance at September 30, 2026 | 62.0 | $0.1 | (10.7) | $(270.7) | $956.6 | $(6.9) | $(365.9) | $313.2 |
| $0.001 Par Value Common Stock · Treasury Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||
| Balance at December 31, 2024 | 59.9 | $0.1 | (5.6) | $(227.7) | $928.0 | $(5.2) | $(212.4) | $482.8 |
| Net income | — | $— | — | $— | $— | $— | $68.0 | $68.0 |
| Stock-based compensation activity | 0.2 | — | — | — | 2.8 | — | — | 2.8 |
| Other comprehensive loss, net of tax | — | — | — | — | — | (0.9) | — | (0.9) |
| Balance at March 31, 2025 | 60.1 | $0.1 | (5.6) | $(227.7) | $930.8 | $(6.1) | $(144.4) | $552.7 |
| Net loss | — | $— | — | $— | $— | $— | $(12.0) | $(12.0) |
| Stock-based compensation activity | 0.3 | — | — | — | 4.4 | — | — | 4.4 |
| Repurchases of common stock | — | — | (1.1) | (6.9) | — | — | — | (6.9) |
| Other comprehensive loss, net of tax | — | — | — | — | — | (2.0) | — | (2.0) |
| Balance at June 30, 2025 | 60.4 | $0.1 | (6.7) | $(234.6) | $935.2 | $(8.1) | $(156.4) | $536.2 |
| Net income | — | $— | — | $— | $— | $— | $51.2 | $51.2 |
| Stock-based compensation activity | 0.2 | — | — | — | 3.4 | — | — | 3.4 |
| Repurchases of common stock | — | — | (1.2) | (8.9) | — | — | — | (8.9) |
| Other comprehensive income, net of tax | — | — | — | — | — | 0.6 | — | 0.6 |
| Balance at September 30, 2025 | 60.6 | $0.1 | (7.9) | $(243.5) | $938.6 | $(7.5) | $(105.2) | $582.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.